Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	February 9, 2021

Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended release injectable suspension)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a confirmed diagnosis of human immunodeficiency virus type -1 (HIV-1).
- Patient was previously on a stable antiviral regimen for a minimum of 6 months.
- Prior to initiating treatment with Cabenuva, patient has documented oral lead-in dosing for 1 month with Vocabria (cabotegravir) and Edurant (rilpivirine).

DOSING AND ADMINISTRATION:

- Oral lead-in dosing: Vocabria (cabotegravir) 30 mg orally once daily in combination with Edurant (rilpivirine) 25 mg orally once daily with a meal.
- Recommended dosing schedule: Cabenuva (600 mg of cabotegravir and 900 mg of rilpivirine) intramuscular (IM) on the last day of oral lead-in and continue with injections of Cabenuva (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.
- Availability:
    - Cabenuva 400-mg/600-mg Kit (single dose vial of 400 mg/2 mL cabotegravir and single dose vial of 600 mg/2 mL rilpivirine)
    - Cabenuva 600-mg/900-mg Kit (single dose vial of 600 mg/3 mL cabotegravir and single dose vial of 900 mg/3 mL rilpivirine)